<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>InflaRx N.V. (IFRX) 周二宣布了关于其在脓疱性坏死性皮肤病中使用 vilobelimab 的三期研究的最新进展，该研究在今年早些时候被终止，因为独立数据监测委员会建议提前停止试验，原因是无效。</p>
<p>最近公布的深入数据分析显示了该治疗的有效性，特别是在溃疡体积减少方面，这进一步支持了 C5a/C5aR 通路在某些中性粒细胞皮肤疾病中的潜在作用。</p>
<p>公司指出，两个连续访视中完全靶向溃疡闭合的主要临床终点显示，vilobelimab 相较于安慰剂的差异为 20.8% 对 16.7%。</p>
<p>与此同时，完全疾病缓解等关键次要终点显示出 vilobelimab 相较于安慰剂的改善。</p>
<p>公司预计将与 FDA 召开会议，讨论 vilobelimab 的潜在前进路径。</p>
<p>在盘前交易时段，IFRX 在纳斯达克下跌 3.93%，至 0.97 美元。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

IFRX

<p>InflaRx N.V. (IFRX) 宣布了其针对脓疱性坏死性皮肤病的第三阶段研究更新，该研究因无效而终止。深入分析显示，vilobelimab 在溃疡体积减少方面的疗效显著，闭合率为 20.8%，而安慰剂为 16.7%。关键的次要终点也支持 vilobelimab。公司计划与 FDA 会面讨论未来的步骤。在盘前交易中，IFRX 股价下跌 3.93%，至 0.97 美元</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>InflaRx N.V. (IFRX), Tuesday announced updates regarding its Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this year after an Independent Data Monitoring Committee recommended the trial be stopped early due to futility.</p>
<div class="lb-trans"><p>InflaRx N.V. (IFRX) 周二宣布了关于其在脓疱性坏死性皮肤病中使用 vilobelimab 的三期研究的最新进展，该研究在今年早些时候被终止，因为独立数据监测委员会建议提前停止试验，原因是无效。</p>
</div><p>The recently announced in-depth data analysis reveals the treatment's efficacy, particularly regarding ulcer volume reduction, which further supports the potential role of the C5a/C5aR pathway in certain neutrophilic skin diseases.</p>
<div class="lb-trans"><p>最近公布的深入数据分析显示了该治疗的有效性，特别是在溃疡体积减少方面，这进一步支持了 C5a/C5aR 通路在某些中性粒细胞皮肤疾病中的潜在作用。</p>
</div><p>The company noted that the primary clinical endpoint of complete target ulcer closure on two consecutive visits showed a difference in favor of vilobelimab over placebo of 20.8 percent versus 16.7 percent.</p>
<div class="lb-trans"><p>公司指出，两个连续访视中完全靶向溃疡闭合的主要临床终点显示，vilobelimab 相较于安慰剂的差异为 20.8% 对 16.7%。</p>
</div><p>Meanwhile, key secondary endpoints such as complete disease remission showed improvement in favor of vilobelimab over placebo.</p>
<div class="lb-trans"><p>与此同时，完全疾病缓解等关键次要终点显示出 vilobelimab 相较于安慰剂的改善。</p>
</div><p>The company expects to have a meeting with the FDA to discuss a potential path forward for vilobelimab.</p>
<div class="lb-trans"><p>公司预计将与 FDA 召开会议，讨论 vilobelimab 的潜在前进路径。</p>
</div><p>In the pre-market hours, IFRX is moving down 3.93 percent, to $0.97 on the Nasdaq.</p>
<div class="lb-trans"><p>在盘前交易时段，IFRX 在纳斯达克下跌 3.93%，至 0.97 美元。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

InflaRx 关于 Vilobelimab 的深入分析，盘前股价下跌